1 Yuen JW & Gohel MD (2005) Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer 53, 11–17.
2 Boh B, Berovic M, Zhang J, et al. (2007) Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 13, 265–301.
3 Shiao MS (2003) Natural products of the medicinal fungus Ganoderma lucidum: occurrence, biological activities, and pharmacological functions. Chem Rec 3, 172–180.
4 Komoda Y, Shimizu M, Sonoda Y, et al. (1989) Ganoderic acid and its derivatives as cholesterol synthesis inhibitors. Chem Pharm Bull (Tokyo) 37, 531–533.
5 Lee SY & Rhee HM (1990) Cardiovascular effects of mycelium extract of Ganoderma lucidum: inhibition of sympathetic outflow as a mechanism of its hypotensive action. Chem Pharm Bull (Tokyo) 38, 1359–1364.
6 Lee JM, Kwon H, Jeong H, et al. (2001) Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytother Res 15, 245–249.
7 Zhu M, Chang Q, Wong LK, et al. (1999) Triterpene antioxidants from Ganoderma lucidum. Phytother Res 13, 529–531.
8 Lai KN, Chan LY, Tang SC, et al. (2006) Ganoderma extract prevents albumin-induced oxidative damage and chemokines synthesis in cultured human proximal tubular epithelial cells. Nephrol Dial Transplant 21, 1188–1197.
9 Hikino H, Konno C, Mirin Y, et al. (1985) Isolation and hypoglycemic activity of ganoderans A and B, glycans of Ganoderma lucidum fruit bodies 1. Planta Med 51, 339–340.
10 Zhang HN & Lin ZB (2004) Hypoglycemic effect of Ganoderma lucidum polysaccharides. Acta Pharmacol Sin 25, 191–195.
11 Seto SW, Lam TY, Tam HL, et al. (2009) Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice. Phytomedicine 16, 426–436.
12 Wachtel-Galor S, Szeto YT, Tomlinson B, et al. (2004) Ganoderma lucidum (‘Lingzhi’); acute and short-term biomarker response to supplementation. Int J Food Sci Nutr 55, 75–83.
13 Wachtel-Galor S, Tomlinson B & Benzie IF (2004) Ganoderma lucidum (‘Lingzhi’), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Br J Nutr 91, 263–269.
14 Stewart PM (2003) Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur J Endocrinol 149, 163–168.
15 Heaney AP, Ferguson T, Sheridan B, et al. (1995) Cortisol excretion in essential hypertension. J Hum Hypertens 9, 947–951.
16 Csabi GY, Juricskay S & Molnar D (2000) Urinary cortisol to cortisone metabolites in hypertensive obese children. J Endocrinol Invest 23, 435–439.
17 van Uum SH, Lenders JW & Hermus AR (2004) Cortisol, 11beta-hydroxysteroid dehydrogenases, and hypertension. Semin Vasc Med 4, 121–128.
18 Benzie IF & Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of ‘antioxidant power’: the FRAP assay. Anal Biochem 239, 70–76.
19 Benzie IF, Chung W & Tomlinson B (1999) Simultaneous measurement of allantoin and urate in plasma: analytical evaluation and potential clinical application in oxidant:antioxidant balance studies. Clin Chem 45, 901–904.
20 Thurnham DI, Davies JA, Crump BJ, et al. (1986) The use of different lipids to express serum tocopherol:lipid ratios for the measurement of vitamin E status. Ann Clin Biochem 23, 514–520.
21 Taylor RL, Machacek D & Singh RJ (2002) Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone. Clin Chem 48, 1511–1519.
22 Schwartz SL (2006) Diabetes and dyslipidaemia. Diabetes Obes Metab 8, 355–364.
23 Kobayashi K, Forte TM, Taniguchi S, et al. (2000) The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism 49, 22–31.
24 de Vries-van der Weij J, Zadelaar S, Toet K, et al. (2009) Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice. Atherosclerosis 206, 153–158.
25 MacLean PS, Bower JF, Vadlamudi S, et al. (2003) Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db/db mice. Arterioscler Thromb Vasc Biol 23, 1412–1415.
26 Tam LS, Tomlinson B, Chu TT, et al. (2007) Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 26, 1495–1498.
27 Tchernof A, Lamarche B, Prud'Homme D, et al. (1996) The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 19, 629–637.
28 Wang SY, Hsu ML, Hsu HC, et al. (1997) The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer 70, 699–705.
29 Li EK, Tam LS, Wong CK, et al. (2007) Safety and efficacy of Ganoderma lucidum (lingzhi) and San Miao San supplementation in patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled pilot trial. Arthritis Rheum 57, 1143–1150.
30 Xi Bao Y, Kwok Wong C, Kwok Ming Li E, et al. (2006) Immunomodulatory effects of lingzhi and san-miao-san supplementation on patients with rheumatoid arthritis. Immunopharmacol Immunotoxicol 28, 197–200.
31 Lam FF, Ko IW, Ng ES, et al. (2008) Analgesic and anti-arthritic effects of Lingzhi and San Miao San supplementation in a rat model of arthritis induced by Freund's complete adjuvant. J Ethnopharmacol 120, 44–50.
32 Wicks SM, Tong R, Wang CZ, et al. (2007) Safety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial. Am J Chin Med 35, 407–414.
33 Armanini D, Fiore C, Mattarello MJ, et al. (2002) History of the endocrine effects of licorice. Exp Clin Endocrinol Diabetes 110, 257–261.
34 Sigurjonsdottir HA, Manhem K, Axelson M, et al. (2003) Subjects with essential hypertension are more sensitive to the inhibition of 11 beta-HSD by liquorice. J Hum Hypertens 17, 125–131.